MA55890A - Modulateurs de thr-beta et leurs procédés d'utilisation - Google Patents

Modulateurs de thr-beta et leurs procédés d'utilisation

Info

Publication number
MA55890A
MA55890A MA055890A MA55890A MA55890A MA 55890 A MA55890 A MA 55890A MA 055890 A MA055890 A MA 055890A MA 55890 A MA55890 A MA 55890A MA 55890 A MA55890 A MA 55890A
Authority
MA
Morocco
Prior art keywords
thr
methods
beta modulators
modulators
beta
Prior art date
Application number
MA055890A
Other languages
English (en)
Other versions
MA55890B1 (fr
Inventor
Jerome Deval
David Mcgowan
Pierre Jean-Marie Bernard Raboisson
Koen Vandyck
Original Assignee
Aligos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aligos Therapeutics Inc filed Critical Aligos Therapeutics Inc
Publication of MA55890A publication Critical patent/MA55890A/fr
Publication of MA55890B1 publication Critical patent/MA55890B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA55890A 2019-05-08 2020-05-07 Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl MA55890B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962845252P 2019-05-08 2019-05-08
US201962944052P 2019-12-05 2019-12-05
US202063005661P 2020-04-06 2020-04-06
PCT/US2020/031904 WO2020227549A1 (fr) 2019-05-08 2020-05-07 MODULATEURS DE THR-β ET LEURS PROCÉDÉS D'UTILISATION
EP20729390.3A EP3965884B1 (fr) 2019-05-08 2020-05-07 Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl

Publications (2)

Publication Number Publication Date
MA55890A true MA55890A (fr) 2022-03-16
MA55890B1 MA55890B1 (fr) 2025-03-28

Family

ID=70919081

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55890A MA55890B1 (fr) 2019-05-08 2020-05-07 Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl

Country Status (32)

Country Link
US (3) US11091467B2 (fr)
EP (2) EP3965884B1 (fr)
JP (2) JP7574223B2 (fr)
KR (1) KR20220017917A (fr)
CN (1) CN114096531B (fr)
AU (1) AU2020267576B2 (fr)
BR (1) BR112021021718A2 (fr)
CA (1) CA3139101A1 (fr)
CL (1) CL2021002883A1 (fr)
CO (1) CO2021015698A2 (fr)
DK (1) DK3965884T3 (fr)
ES (1) ES3020290T3 (fr)
FI (1) FI3965884T3 (fr)
GE (2) GEP20247637B (fr)
HR (1) HRP20250384T1 (fr)
HU (1) HUE070650T2 (fr)
IL (1) IL287720A (fr)
LT (1) LT3965884T (fr)
MA (1) MA55890B1 (fr)
MD (1) MD3965884T2 (fr)
MX (1) MX2021013472A (fr)
MY (1) MY210357A (fr)
PE (1) PE20220255A1 (fr)
PH (1) PH12021552782A1 (fr)
PL (1) PL3965884T3 (fr)
PT (1) PT3965884T (fr)
RS (1) RS66686B1 (fr)
SG (1) SG11202111552YA (fr)
SI (1) SI3965884T1 (fr)
TW (1) TWI855068B (fr)
WO (1) WO2020227549A1 (fr)
ZA (1) ZA202409114B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
KR20220017917A (ko) 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
EP4017875A4 (fr) * 2019-08-23 2023-05-03 Terns Pharmaceuticals, Inc. Composés agonistes du récepteur bêta de l'hormone thyroïdienne
AU2020346057A1 (en) 2019-09-12 2022-04-21 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3158379A1 (fr) * 2019-11-26 2021-06-03 Hejun Lv Compose de 1,2,4-triazine-3,5-dione, son procede de preparation et son utilisation
CN114787153A (zh) 2019-12-26 2022-07-22 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
KR20230048481A (ko) * 2020-06-02 2023-04-11 쳉두 캉홍 파마슈티칼 코., 엘티디. 새로운 갑상선 호르몬 β 수용체 효능제
US12528761B2 (en) 2020-06-17 2026-01-20 Autobahn Therapeutics, Inc. Thyromimetics
WO2022053028A1 (fr) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 Composé de 1,2,4-triazine-3,5-(2h,4h)-dicétone et son utilisation
AU2021341182A1 (en) * 2020-09-10 2023-04-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of resmetirom, preparation method therefor, and use thereof
EP4215524A4 (fr) * 2020-09-17 2024-10-02 Sunshine Lake Pharma Co., Ltd. Composé servant d'agoniste du récepteur beta de l'hormone thyroïdienne et utilisations du composé
CA3197234A1 (fr) * 2020-11-06 2022-05-12 David Craig Mcgowan Derives de pyridazinone en tant qu'agonistes du recepteur thyroidien et leurs utilisations
AU2021373043A1 (en) 2020-11-06 2023-06-15 Aligos Therapeutics, Inc. Oxindoles and methods of use thereof
CN114591300A (zh) * 2020-12-04 2022-06-07 南京圣和药业股份有限公司 作为THRβ激动剂的杂环化合物及其应用
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114685450A (zh) * 2020-12-30 2022-07-01 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
US20240059682A1 (en) * 2021-03-03 2024-02-22 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
US20240083860A1 (en) * 2021-03-04 2024-03-14 Fukang (Shanghai) Health Technology Co., Ltd Aromatic compound, preparation method therefor, and application thereof
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
CN117279911B (zh) * 2021-05-21 2025-07-08 深圳微芯生物科技股份有限公司 一种杂环化合物及其应用
WO2023023474A1 (fr) * 2021-08-16 2023-02-23 Senya Pharmaceuticals, Inc. Modulateurs du tr-bêta, compositions pharmaceutiques et applications thérapeutiques
KR20240112993A (ko) 2021-09-01 2024-07-19 알리고스 테라퓨틱스 인코포레이티드 Pnpla3-표적화 짧은 간섭 rna(sirna) 분자 및 이의 용도
KR20240053635A (ko) 2021-09-08 2024-04-24 알리고스 테라퓨틱스 인코포레이티드 변형된 짧은 간섭 핵산 (sina) 분자 및 그의 용도
CN116354934A (zh) * 2021-12-28 2023-06-30 中国科学院上海药物研究所 一类喹啉类化合物及其制备方法、药物组合物和用途
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途
WO2024182446A2 (fr) 2023-02-28 2024-09-06 Aligos Therapeutics, Inc. Molécules d'arn interférent court (arnsi) ciblant pnpla3 et leurs utilisations
US20240352464A1 (en) 2023-03-07 2024-10-24 Aligos Therapeutics, Inc. Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
WO2024211898A1 (fr) 2023-04-07 2024-10-10 Terns Pharmaceuticals, Inc. Association comprenant un agoniste thrbeta anda glp-1r destiné à être utilisé dans le traitement d'un trouble du foie ou d'une maladie cardiométabolique
WO2024260309A1 (fr) * 2023-06-19 2024-12-26 西威埃医药技术（上海）有限公司 AGONISTE DU RÉCEPTEUR THR-β, SON PROCÉDÉ DE PRÉPARATION ET SON PROCÉDÉ D'UTILISATION
WO2025011259A1 (fr) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 Forme cristalline de resmetirom, son procédé de préparation et son utilisation
CN117327057B (zh) * 2023-08-30 2026-03-03 南京雷正医药科技有限公司 一类作为甲状腺激素受体激动剂的三嗪二酮类化合物及其合成、用途
WO2025137568A1 (fr) * 2023-12-21 2025-06-26 Aligos Therapeutics, Inc. Modulateurs de thr-bêta et leurs méthodes d'utilisation
US20250340541A1 (en) 2024-05-03 2025-11-06 Aligos Therapeutics, Inc. Methods of preparing modulators of thr-beta
WO2025252147A1 (fr) * 2024-06-07 2025-12-11 珠海联邦制药股份有限公司 COMPOSÉ D'AGONISTE DU RÉCEPTEUR DES HORMONES THYROÏDIENNES DE TYPE β ET SON UTILISATION
WO2026050911A1 (fr) * 2024-09-04 2026-03-12 西威埃医药技术（上海）有限公司 FORME CRISTALLINE D'UN AGONISTE SÉLECTIF TR-β, PROCÉDÉ DE PRÉPARATION ET UTILISATION
CN120923503A (zh) * 2025-10-10 2025-11-11 吉斯凯(苏州)制药有限公司 具有杂环结构的化合物、THRβ受体激动剂及用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
ATE337009T1 (de) 2001-05-31 2006-09-15 Pfizer Prod Inc Medizinische verwendung thyromimetischer verbindungen gegen haarausfall und zusammensetzungen
EP1471049A4 (fr) 2002-01-30 2006-08-16 Kissei Pharmaceutical Nouveau ligand de recepteur de l'hormone thyroidienne, preparations medicinales le contenant et leur utilisation
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
WO2004047827A1 (fr) 2002-11-25 2004-06-10 Pfizer Products Inc. Procede permettant de promouvoir la croissance des ongles a l'aide de composes thyromimetiques
CA2614529C (fr) 2005-07-21 2011-06-28 F. Hoffmann-La Roche Ag Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone thyroidienne
KR20080087833A (ko) * 2005-12-21 2008-10-01 쉐링 코포레이션 히스타민 ｈ３ 길항제로서 유용한 페녹시피페리딘 및 이의유사체
KR20090025367A (ko) * 2006-06-28 2009-03-10 가부시키가이샤산와카가쿠켄큐쇼 신규 6-5계 이환식 복소환 유도체 및 그 의약용도
WO2008104752A1 (fr) * 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropytidones inhibiteurs d'élastase
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
AU2010240200B2 (en) 2009-04-20 2014-03-13 Mitsubishi Tanabe Pharma Corporation Novel thyroid hormone beta receptor agonist
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
DK2695611T3 (en) 2012-08-06 2015-01-05 Wolff August Gmbh & Co Kg Arzneimittel Dr Eprotirome for use in the prevention and / or treatment of hair disorders and their compositions
EP4023641B1 (fr) * 2012-09-17 2024-05-01 Madrigal Pharmaceuticals, Inc. Procédé de synthèse d'analogues de l'hormone thyroïdienne et de ses polymorphes
JP6333372B2 (ja) 2013-07-09 2018-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤の組み合わせ
US10303567B2 (en) 2013-08-15 2019-05-28 Entit Software Llc Managing database nodes
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
CA2972919A1 (fr) 2015-01-09 2016-07-14 Gilead Apollo, Llc Therapie combinee a base d'un inhibiteur de l'acc utilisable en vue du traitement de la steatose hepatique non alcoolique
SG10202012080UA (en) 2016-06-03 2021-01-28 Chemocentryx Inc Method of treating liver fibrosis
ES2924257T3 (es) 2016-10-18 2022-10-05 Madrigal Pharmaceuticals Inc Métodos de tratar trastornos hepáticos o trastornos lipídicos con un agonista de THR-beta
BR112019018162A2 (pt) 2017-03-13 2020-04-07 Genfit Composições farmacêuticas para terapia de combinação
CN110536682B (zh) 2017-04-18 2023-01-06 基恩菲特公司 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
EP3655780B1 (fr) 2017-07-19 2021-11-10 Bio-Rad Europe GmbH Combinaisons de biomarqueurs pour évaluer une stéatohépatite non alcoolique et/ou un état de fibrose hépatique
WO2019099457A1 (fr) 2017-11-14 2019-05-23 Quixgen, Inc. Composés de benzodioxinone
ES2996688T3 (en) 2017-12-06 2025-02-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
EP3725779A4 (fr) 2018-01-23 2021-02-24 Shenzhen TargetRx, Inc. Composé de pyridazinone substitué
WO2019178023A1 (fr) 2018-03-12 2019-09-19 Yale University Procédés de traitement ou de prévention du syndrome de détresse respiratoire aiguë
WO2019213611A1 (fr) 2018-05-04 2019-11-07 Cirius Therapeutics, Inc. Analogues de thiazolidinedione pour le traitement de nafld et de maladies métaboliques
CN108727344A (zh) 2018-05-14 2018-11-02 嘉兴特科罗生物科技有限公司 一种化合物及其合成方法和应用
KR102531771B1 (ko) * 2018-06-12 2023-05-11 스촨 하이스코 파마수티컬 씨오., 엘티디 갑상선 호르몬 수용체 작용제 및 그 용도
US11992560B2 (en) 2018-06-14 2024-05-28 Alma Mater Studiorum—Università di Bologna Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug
US20210292304A1 (en) 2018-06-22 2021-09-23 Hinova Pharmaceuticals Inc. Deuterated mgl-3196 compound and use thereof
TW202019914A (zh) 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式
TWI825144B (zh) 2018-08-10 2023-12-11 美商思達利醫藥公司 第二型轉麩醯胺酸酶(tg2)抑制劑
US10800767B2 (en) 2018-08-24 2020-10-13 Terns, Inc. Thyroid hormone receptor beta agonist compounds
KR20210076932A (ko) * 2018-10-12 2021-06-24 인벤티스바이오 컴퍼니 리미티드 갑상선 호르몬 수용체 작용제
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN119431265A (zh) 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
KR20220017917A (ko) * 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
CN111909137B (zh) 2019-05-10 2023-05-30 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
IT201900006923A1 (it) 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
CN114174282A (zh) 2019-05-29 2022-03-11 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
TW202115029A (zh) 2019-07-31 2021-04-16 大陸商深圳微芯生物科技股份有限公司 雜環化合物及其用途
US12378268B2 (en) 2019-08-19 2025-08-05 Hepagene Therapeutics (HK) Limited Heterocyclic THR-β receptor agonist compound and preparation method and use therefor
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
EP4017875A4 (fr) 2019-08-23 2023-05-03 Terns Pharmaceuticals, Inc. Composés agonistes du récepteur bêta de l'hormone thyroïdienne
WO2021043185A1 (fr) 2019-09-04 2021-03-11 Sunshine Lake Pharma Co., Ltd. Composé utilisé comme agoniste du récepteur bêta des hormones thyroïdiennes et son utilisation
AU2020346057A1 (en) 2019-09-12 2022-04-21 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4036090A4 (fr) 2019-09-24 2023-11-15 Sunshine Lake Pharma Co., Ltd. Composé chimique en tant qu'agoniste du récepteur bêta de l'hormone thyroïdienne et son utilisation
CN112707892A (zh) 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
CA3158379A1 (fr) 2019-11-26 2021-06-03 Hejun Lv Compose de 1,2,4-triazine-3,5-dione, son procede de preparation et son utilisation
EP4090652A1 (fr) 2020-01-13 2022-11-23 Eccogene (Shanghai) Co., Ltd. Triazinones substituées en tant qu'agonistes du récepteur de l'hormone thyroïdienne
KR20230006482A (ko) 2020-04-06 2023-01-10 바스프 에스이 살충제로서의 이미다조-피리미돈 화합물

Also Published As

Publication number Publication date
CN114096531A (zh) 2022-02-25
JP2022532706A (ja) 2022-07-19
DK3965884T3 (da) 2025-03-31
HRP20250384T1 (hr) 2025-05-23
MX2021013472A (es) 2022-01-06
IL287720A (en) 2021-12-01
AU2020267576A1 (en) 2021-12-09
SG11202111552YA (en) 2021-11-29
US20210355112A1 (en) 2021-11-18
KR20220017917A (ko) 2022-02-14
HUE070650T2 (hu) 2025-06-28
LT3965884T (lt) 2025-04-10
US11091467B2 (en) 2021-08-17
MY210357A (en) 2025-09-13
FI3965884T3 (fi) 2025-04-02
EP4523692A2 (fr) 2025-03-19
US20200354345A1 (en) 2020-11-12
EP3965884B1 (fr) 2025-01-15
US12180192B2 (en) 2024-12-31
JP7574223B2 (ja) 2024-10-28
CN114096531B (zh) 2026-03-10
PE20220255A1 (es) 2022-02-16
ZA202409114B (en) 2025-06-25
BR112021021718A2 (pt) 2022-01-18
GEAP202415821A (en) 2024-03-11
WO2020227549A8 (fr) 2021-05-27
EP4523692A3 (fr) 2025-06-04
MD3965884T2 (ro) 2025-05-31
TWI855068B (zh) 2024-09-11
EP3965884A1 (fr) 2022-03-16
PH12021552782A1 (en) 2023-01-16
CA3139101A1 (fr) 2020-11-12
TW202108569A (zh) 2021-03-01
GEP20247637B (en) 2024-06-25
CO2021015698A2 (es) 2022-01-17
ES3020290T3 (en) 2025-05-22
AU2020267576B2 (en) 2025-03-13
WO2020227549A1 (fr) 2020-11-12
US20250304561A1 (en) 2025-10-02
PT3965884T (pt) 2025-03-31
PL3965884T3 (pl) 2025-05-05
SI3965884T1 (sl) 2025-05-30
JP2025011262A (ja) 2025-01-23
RS66686B1 (sr) 2025-05-30
CL2021002883A1 (es) 2022-10-28
MA55890B1 (fr) 2025-03-28

Similar Documents

Publication Publication Date Title
MA55890A (fr) Modulateurs de thr-beta et leurs procédés d'utilisation
MA56457A (fr) Modulateurs de hsd17b13 et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
EP3968999A4 (fr) Inhibiteurs de fgfr et leurs procédés d'utilisation
EP3911648A4 (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP3775203A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3810185A4 (fr) Variants d'interleukine-2 et leurs procédés d'utilisation
EP3911640A4 (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP3634430A4 (fr) Agents multibiotiques et procédés d'utilisation de ceux-ci
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
MA51837A (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
EP3962479A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3893917A4 (fr) Compositions d'il-15 et leurs procédés d'utilisation
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
EP3790572A4 (fr) Variants du récepteur de l'activine de type iia et leurs procédés d'utilisation
EP3962481A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3941475A4 (fr) Pyridazinones et leurs procédés d'utilisation
MA71645A (fr) Pyridazinones et leurs procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP4034605A4 (fr) Compositions de polissage et leurs procédés d'utilisation
EP3930901A4 (fr) Dispositifs micro-fluidiques numériques et leurs procédés d'utilisation
EP3688373A4 (fr) Brûleurs et leurs procédés d'utilisation
EP3836971A4 (fr) Conjugués et leurs procédés d'utilisation
MA53328A (fr) Anticorps anti-siglec-5 et leurs procédés d'utilisation
EP4045226A4 (fr) Compositions de polissage et leurs procédés d'utilisation